Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib

BACKGROUND: In metastatic renal cell carcinoma (mRCC) patients treated with targeted agents and their primary tumor (PT) in situ, early PT decrease in size correlates with improved overall PT response, but the effect on overall survival (OS) is unknown. OBJECTIVE: To evaluate whether early PT size r...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur Urol
Asıl Yazarlar: Abel, E. Jason, Culp, Stephen H., Tannir, Nizar M., Tamboli, Pheroze, Matin, Surena F., Wood, Christopher G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378714/
https://ncbi.nlm.nih.gov/pubmed/21784574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2011.07.008
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller